Alembic Limited (ALEMBICLTD) AI Stock Analysis

• Market Cap: ₹25.59B
• Dividend Yield: 2.41%
• Average Volume (3M): 26.19K
• Price to Earnings (P/E): 8.4
• Beta (1Y): 1.52
• Revenue Growth: 28.84%
• EPS Growth: 13.01%
• Country: IN
• Employees: 285
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.40
• Shares Outstanding: 256,781,830
• 10 Day Avg. Volume: 29,461
• 30 Day Avg. Volume: 26,190
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹126.00
• Price Target Upside: 26.44% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 68 Neutral
• Price Target: ₹126.00 ▲(26.44% Upside)

The overall score reflects strong financial health and undervaluation, counterbalanced by mixed technical trends and concerns over the sustainability of profit margins. The absence of earnings call data limits the assessment of future outlook.

Alembic Limited Business Overview & Revenue Model

Company Description

Alembic Limited engages in the manufacturing and marketing of fermentation and chemistry based active pharmaceuticals ingredients (API). It operates through API and Real Estate segments. The company is also involved in the construction of residential and commercial real estate projects; provision of project management and marketing consultancy services; and leasing of commercial properties. In addition, it operates co-generation plants with a total capacity of 11 MW; and wind power plants with a total capacity of 5 MW. The company also exports its products. Alembic Limited was founded in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Limited.

How the Company Makes Money

Alembic Limited generates revenue primarily through the sale of its pharmaceutical products, including APIs and finished formulations. The company's revenue streams are diversified across domestic and international markets, with a strong focus on exports to regulated markets such as the United States and Europe. Key factors contributing to Alembic's earnings include its robust product pipeline, strategic partnerships with global pharmaceutical companies, and investments in research and development to innovate and expand its product portfolio. Additionally, Alembic leverages its manufacturing capabilities to offer contract manufacturing services, further enhancing its revenue potential.

Alembic Limited Financial Statement Overview

Summary

Alembic Limited shows strong revenue growth and profitability with a healthy balance sheet. The unusually high net profit margin suggests potential one-time gains, raising concerns about sustainability despite improved cash flow management.

Income Statement

Alembic Limited shows strong revenue growth with a 50.8% increase from 2024 to 2025, demonstrating robust expansion in the specialty and generic drug market. The gross profit margin is healthy at 68.8% for 2025, reflecting effective cost management. However, the net profit margin is unusually high at 140%, likely due to one-time gains or accounting adjustments, which could be an anomaly. The EBIT margin of 37.4% and EBITDA margin of 76% indicate strong core operational profitability.

Balance Sheet

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.006 in 2025, signifying low leverage and financial risk. The equity ratio stands robust at 93.4%, showing a strong capital structure. Return on Equity (ROE) is high at 13.3%, driven by substantial net income, but this figure may be inflated by non-recurring items. Overall, the balance sheet reflects financial stability, though the high net income may not be sustainable.

Cash Flow

The cash flow statement reveals a positive shift in free cash flow, from negative in 2024 to positive in 2025, indicating improved cash generation. The operating cash flow to net income ratio of 0.28 suggests moderate cash conversion efficiency. The free cash flow to net income ratio of 0.11 is low, hinting at potential cash flow challenges despite high net income figures. The company shows progress in cash flow management, but sustainability remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.22B	2.22B	1.47B	1.18B	713.69M	678.37M
Gross Profit	1.53B	1.53B	872.46M	702.07M	404.50M	392.74M
EBITDA	1.69B	1.69B	1.05B	939.86M	1.03B	213.43M
Net Income	3.11B	3.11B	2.69B	1.91B	2.22B	3.43B
Balance Sheet
Total Assets	25.03B	25.03B	23.29B	22.05B	26.32B	24.09B
Cash, Cash Equivalents and Short-Term Investments	594.70M	594.70M	129.05M	464.09M	270.77M	225.14M
Total Debt	144.50M	144.50M	91.49M	0.00	0.00	2.77M
Total Liabilities	1.64B	1.64B	1.43B	1.27B	1.35B	1.12B
Stockholders Equity	23.39B	23.39B	21.86B	20.78B	24.97B	22.97B
Cash Flow
Free Cash Flow	0.00	356.00M	-336.03M	130.35M	-535.60M	-496.37M
Operating Cash Flow	0.00	863.70M	226.87M	388.52M	-177.47M	-21.82M
Investing Cash Flow	0.00	-265.80M	258.36M	72.96M	188.48M	-348.69M
Financing Cash Flow	0.00	-583.40M	-481.94M	-463.88M	-58.16M	-153.62M

Alembic Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 99.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Negative. The current price of 99.65 is below the 20-day moving average (MA) of 104.41, below the 50-day MA of 107.41, and below the 200-day MA of 109.46, indicating a bearish trend. The MACD of -1.01 indicates Positive momentum. The RSI at 33.13 is Neutral, neither overbought nor oversold. The STOCH value of 11.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALEMBICLTD.

Alembic Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	78 Outperform	₹633.42B	18.68	10.68%	0.37%	7.76%	-2.84%
ALKEM	72 Outperform	₹648.75B	28.40	18.07%	0.83%	4.49%	11.22%
ALEMBICLTD	68 Neutral	₹25.59B	8.37	―	2.41%	28.84%	13.01%
IPCALAB	63 Neutral	₹347.67B	44.66	10.62%	0.29%	11.49%	35.00%
APLLTD	60 Neutral	₹178.74B	29.64	11.24%	1.21%	8.20%	-4.26%
GLENMARK	54 Neutral	₹556.02B	73.77	11.83%	0.13%	10.99%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alembic Limited Corporate Events

Alembic Limited Updates Registrar Contact Details

Alembic Limited announced a change in the email and website address of its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This update is part of a continued effort to streamline communication and improve service efficiency for shareholders, reflecting the company’s commitment to maintaining effective stakeholder relations.